Nitroglycerin Aloe Vera Gel for Angina

Formulation and Evaluation of Nitroglycerin Aloe Vera Gel for Angina - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/076947

Enrollment

100

Registered

2024-11-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I999- Unspecified disorder of circulatory system

Interventions

Intervention1: Nitroglycerin 6% Aloe Vera Gel: Route: Topically to the skin (e.g., chest or upper arms) Dose: measured dose of the nitroglycerin 6% aloe vera gel Frequency: once daily or during ang

Eligibility

Inclusion criteria

Inclusion criteria: • Patient at least 25-60-year-old. • Patient with suspected s angina pectoris who undergo coronary angiography • Breast feeding mothers • Intestinal angina • Hypertensive patient • Abdominal infarction • Pregnant female

Exclusion criteria

Exclusion criteria: • severe myocardial infarction • Cardiogenic shock • Severe heart faliure • Hypersensitive to medicine • Severe hypotension • Cardiac temponade

Design outcomes

Primary

Measure	Time frame
Efficacy of the 6% nitroglycerin aloe vera gel in relieving angina symptoms through topical administration. To assess the safety and tolerability of the gel. To compare the onset and duration of action of the gel with other forms of nitroglycerin (e.g., sublingual tablets). To evaluate patient compliance and usability of the gel. To measure improvements in quality of life in patients with chronic angina.Timepoint: baseline and after 4 hrs. when angina settled	—

Measure

Time frame

Efficacy of the 6% nitroglycerin aloe vera gel in relieving angina symptoms through topical administration. To assess the safety and tolerability of the gel. To compare the onset and duration of action of the gel with other forms of nitroglycerin (e.g., sublingual tablets). To evaluate patient compliance and usability of the gel. To measure improvements in quality of life in patients with chronic angina.Timepoint: baseline and after 4 hrs. when angina settled

—

Secondary

Measure	Time frame
Breathing patternTimepoint: Baseline & after 4 hrs	—

Countries

Pakistan

Contacts

Public ContactImran Ahmad Khan

Department of Pharmacy, MNS University of Agriculture, Multan, Pakistan

imranahmadkhandurrani@gmail.com03336120602

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026